Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily SignalsNeutral

2760 companies scored · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2760 IC ≥ 0 · market cap ≥ $100M
Median forecast +2.41% Total · 90D
Long–short spread +6.40% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 171 ▼ 376 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · Neutral

53 companies

Sorted by 90D forecast ↓

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
51 ELANElanco Animal Health Inc Life Sciences 0.37 $11.8B Neutral +0.54% +2.02% ·
52 DBVTDBV Technologies S.A. Life Sciences 0.35 $536M Neutral +0.52% +1.91% ·
53 BMRNBIOMARIN PHARMACEUTICAL INC Life Sciences 0.31 $10.6B Neutral +0.55% +1.90% ▲ 1
51–53 of 53 Previous Next
Since the previous run

Rating changes

▲ 171▼ 376
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.